- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00903994
A Pilot Study on the Onset of Action of KTP, 20% in the Treatment of Acute Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee (KTP)
February 17, 2020 updated by: APR Applied Pharma Research s.a.
An Open-Label, Phase II, Pilot Study on the Onset of Action of KTP, 20% in the Treatment of Acute Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee
Open-label study to be conducted at 2 US investigational sites in subjects who have acute tendonitis or bursitis of the shoulder, elbow, or knee.
Eligible subjects receive treatment with the KTP, applied once daily at the same application site for 3 consecutive days.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85050
- HOPE Research Institute, LLC
-
-
Georgia
-
Stockbridge, Georgia, United States, 30281
- CPI, Clinical Research Atlanta
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Are males or females 18 years of age or older (If female, must be practicing abstinence or using a medically acceptable form of contraception (e.g., intrauterine device, hormonal birth control, or double barrier method). For the purpose of this study, all females are considered to be of childbearing potential unless they are post-menopausal, biologically sterile, or surgically sterile (i.e., hysterectomy, bilateral oophorectomy), or have undergone tubal ligation for greater than or equal to one year.)
- Have a diagnosis of acute tendonitis or bursitis of the shoulder, elbow or knee with acute onset of the current episode in the 15 days preceding the screening visit
- Have average pain intensity during daily activities over the past 24 hours rated 5 or greater on an 11-point scale (range 0 to 10). (If the onset of acute tendonitis or bursitis is less than 24 hours before the screening visit, the patient will rate the average pain intensity during daily activity since the time of onset.) Site personnel must not reveal this eligibility criterion to prospective patients.
- Are willing to discontinue use of all analgesic medications (including over-the-counter [OTC] analgesics) except the study patch. Note: Aspirin at a daily dose of 81 mg per day for cardiovascular prophylaxis will be allowed.
- Have been informed of the nature of the study and have provided written informed consent
Exclusion Criteria:
- Have a positive urine pregnancy test (females of childbearing potential only) or are pregnant or lactating
- Have tendonitis or bursitis secondary to a systemic inflammatory disease (e.g., rheumatoid arthritis, spondyloarthropathies), or resulting from calcification or requiring surgery
- Have had pharmacologic treatment (e.g., analgesic medications except 81mg prophylactic aspirin) less than 12 hours before the baseline assessments
- Have received systemic corticosteroids in the 30 days preceding the screening visit (e.g., intra-articular, peritendinous, oral, or parenteral administration). Nasal inhalation steroids are permitted.
- Have received any pharmacologic treatment or physical therapy in the past 6 months for the joint targeted for this study. Pharmacologic treatment or physical therapy for current tendonitis or bursitis is allowed unless the medication or therapy is prohibited by the protocol.
- Require continued use of an immobilization device for treatment of the current episode of tendonitis or bursitis
- Have a history or physical examination finding that is incompatible with safe participation in the study, including GI ulcer or bleeding, anemia or prolonged bleeding time
- Have a history, or physical examination finding, that is incompatible with study product use or with obtaining robustly interpretable data, chronic skin conditions such as psoriasis, clinically significant osteoarthritis, or skin lesions or wounds at the affected site
- Have a history of drug or alcohol abuse
Are taking medications or other substances contraindicated due to the nature of the study medication or the potential for drug interactions. This includes:
- patients with allergies to prescription or OTC products containing NSAIDs
- patients in whom aspirin or other NSAIDs or analgesic drugs induce the syndrome of asthma, rhinitis and nasal polyps
- patients taking medications that may affect clotting, for example warfarin, parenteral heparin, ticlopidine (Ticlid®) or clopidogrel (Plavix®)
- patients taking lithium
- patients taking methotrexate
- Are renally or hepatically impaired in the judgment of the investigator based on the patient's medical history or other available clinical laboratory information
- Are taking sleep medications, muscle relaxants, anticonvulsants or antidepressants at a dose that has not been stable for at least 3 months
- Receiving physical therapy for the tendonitis/bursitis. Ongoing, stable physical therapy for conditions not related to tendonitis/bursitis is allowed.
- Have scheduled elective surgery or other invasive procedures during the period of study participation
- Have any illness or concurrent condition that would, in the opinion of the investigator or medical monitor, make study participation unsafe or would confound study results (e.g.,inflammatory arthritis, spondyloarthropathies, fibromyalgia, or are currently undergoing treatment for chronic pain)
- Have received an investigational drug or product or participated in an investigational drug study within a period of 30 days prior to receiving study medication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Single Arm
|
Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for
the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure the time to onset of action of the KTP in the treatment of pain associated with acute tendonitis or bursitis of the shoulder, elbow, or knee as measured by the time to meaningful pain relief.
Time Frame: 3 consecutive days
|
3 consecutive days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess the safety and tolerability of the KTP as measured by adverse events cutaneous AEs, assessments of local tolerability and patch adherence, and vital signs
Time Frame: 3 consecutive days
|
3 consecutive days
|
Assess the time to first perceptible pain relief
Time Frame: 3 consecutive days
|
3 consecutive days
|
Assess the effect of KTP in the treatment of pain associated with acute tendonitis or bursitis of the shoulder, elbow or knee as measured by pain intensity during activity and pain relief.
Time Frame: 3 consecutive days
|
3 consecutive days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2007
Primary Completion (Actual)
August 1, 2007
Study Completion (Actual)
August 1, 2007
Study Registration Dates
First Submitted
May 15, 2009
First Submitted That Met QC Criteria
May 18, 2009
First Posted (Estimate)
May 19, 2009
Study Record Updates
Last Update Posted (Actual)
February 18, 2020
Last Update Submitted That Met QC Criteria
February 17, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Wounds and Injuries
- Joint Diseases
- Musculoskeletal Diseases
- Muscular Diseases
- Tendon Injuries
- Tendinopathy
- Acute Pain
- Bursitis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ketoprofen
Other Study ID Numbers
- EN3269-201
- Ketoprofen Topical Patch, 20%
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tendonitis of the Shoulder, Elbow, or Knee
-
Cerimon PharmaceuticalsPPDCompletedRotator Cuff Tendonitis | Bicipital Tendonitis | Subdeltoid Bursitis of the Shoulder | Subacromial Bursitis of the Shoulder | Medial Epicondylitis of the Elbow | Lateral Epicondylitis of the Elbow | DeQuervain's Tenosynovitis of the WristUnited States
-
Arthrex, Inc.RecruitingDegenerative and Traumatic Pathology of the Knee | Degenerative and Traumatic Pathology of the Shoulder and Elbow | Degenerative and Traumatic Pathology of the Foot and Ankle | Degenerative and Traumatic Pathology of the Hand and Wrist | Degenerative and Traumatic Pathology of the HipUnited States, United Kingdom, Canada, Puerto Rico, South Africa
-
Helsinki University Central HospitalRecruitingCultural Adaptation of Shoulder and Elbow PROMs | Definition of the Patients Acceptable Symptomatic State | Definition of the Minimal Important DifferenceFinland
-
Allentown Anesthesia AssociatesSonoSite, Inc.CompletedTrauma to the Arm, Shoulder, Elbow, Forearm, or HandUnited States
-
Universidad Rey Juan CarlosCompleted
-
Xiangya Hospital of Central South UniversityActive, not recruitingKnee Arthropathy | Hip Arthropathy | Ankle Arthropathy | Elbow Arthropathy | Shoulder ArthropathyChina
-
Peking University Third HospitalRecruiting
-
Region SkaneRecruitingOsteoarthritis of the Knee or HipSweden
-
Regeneron PharmaceuticalsTeva Pharmaceutical Industries, Ltd.CompletedOsteoarthritis of the Knee or HipUnited States, Bulgaria, Chile, Colombia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Lithuania, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Ukraine, United Kingdom
-
International Clinical Research InstituteCompletedEpicondylitis of the ElbowUnited States
Clinical Trials on Ketoprofen Topical Patch 20%
-
Hisamitsu Pharmaceutical Co., Inc.Completed
-
Hisamitsu Pharmaceutical Co., Inc.Completed
-
Hisamitsu Pharmaceutical Co., Inc.CompletedOsteoarthritis of the KneeUnited States
-
APR Applied Pharma Research s.a.CompletedBursitis | TendonitisUnited States
-
APR Applied Pharma Research s.a.CompletedSprain | StrainUnited States
-
APR Applied Pharma Research s.a.CompletedOsteoarthritisUnited States
-
Endo PharmaceuticalsTerminatedBursitis | TendonitisUnited States
-
Hisamitsu Pharmaceutical Co., Inc.Completed
-
ZARS Pharma Inc.CompletedOsteoarthritisUnited States
-
Northwell HealthSolace Brands, Inc.WithdrawnOsteoarthritis | Knee Osteoarthritis | CBDUnited States